LON:ONC Oncimmune (ONC) Share Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free ONC Stock Alerts GBX 25.40 +1.30 (+5.39%) (As of 05/3/2024 02:12 PM ET) Add Compare Share Share Today's Range 25.40▼ 25.4050-Day Range 16.80▼ 30.4252-Week Range 13▼ 45Volume37,641 shsAverage Volume74,602 shsMarket Capitalization£18.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Oncimmune alerts: Email Address Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Oncimmune Stock (LON:ONC)Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.Read More ONC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONC Stock News HeadlinesMarch 19, 2024 | wsj.comOncimmune Holdings PLCMarch 2, 2024 | finance.yahoo.comOncimmune Holdings Full Year 2023 Earnings: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)May 6, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 15, 2024 | reuters.comCancer test firm Freenome raises $254 mln in fresh fundingFebruary 14, 2024 | msn.comActivist investor Kelso gains board seats at The Works as it tries to enhance shareholder valueDecember 2, 2023 | proactiveinvestors.com.auOncimmune seeing commercial traction as it inks new deals with big pharma companiesSeptember 26, 2023 | yahoo.comThe Unique Use of Liquid BiopsyAugust 1, 2023 | marketwatch.comOncimmune's Acting CEO Ron Kirschner Steps Down, Takes COO Role; Gouldstone Starts as CEOMay 6, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. July 14, 2023 | marketwatch.comOncimmune Shares Fall As Company Lowers FY 2022 Revenue ResultJuly 12, 2023 | lse.co.ukOncimmune names chief executive successor, while finance chief leavesJuly 12, 2023 | marketwatch.comOncimmune Holdings Appoints Martin Gouldstone CEO; CFO Matthew Hall to Step DownJune 23, 2023 | lse.co.ukOncimmune Holdings shakes up leadership and unveils new growth planJune 23, 2023 | marketwatch.comOncimmune CEO Adam Hill to Step Down; Sees Tough End to FY 2023May 31, 2023 | lse.co.ukOncimmune shares plummet as interim revenue falls by fifthMay 31, 2023 | marketwatch.comOncimmune Shares Fall on 1H Pretax LossMay 22, 2023 | lse.co.ukOncimmune sells two subsidiaries to Freenome for GBP13 millionMay 22, 2023 | markets.businessinsider.comFREENOME ACQUIRES GLOBAL IMMUNODIAGNOSTICS DEVELOPER ONCIMMUNE LTDMay 22, 2023 | marketwatch.comOncimmune Eases Going-Concern Risk With Sale of Two Subsidiaries for GBP13 MlnApril 28, 2023 | marketwatch.comThe Comprehensive Guide to the Cancer Biopsy Market: Trends and Revenue Forecast with predicted CAGR of 4.2% from 2023-2030April 22, 2023 | marketwatch.comCancer Biopsy Market Outlook by 2031April 12, 2023 | finance.yahoo.comOncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual ConferenceFebruary 28, 2023 | proactiveinvestors.comOncimmune delivering top-line growthFebruary 27, 2023 | marketwatch.comOncimmune Shares Fall After Going Concern Warning, Pretax LossFebruary 20, 2023 | lse.co.ukCORRECT: Oncimmune works with Siemens Healthineers on cancer therapyJanuary 25, 2023 | theguardian.comRichard Sharp: BBC chair was shareholder in firm awarded £600k while he was a No 10 adviserJanuary 2, 2023 | finance.yahoo.comInvestors in Oncimmune Holdings (LON:ONC) have unfortunately lost 67% over the last yearSee More Headlines Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2018Today5/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ONC CUSIPN/A CIKN/A Weboncimmune.com Phone+44-115-8231869FaxN/AEmployees52Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.08) Trailing P/E RatioN/A Forward P/E Ratio29.40 P/E GrowthN/ANet Income£-6,150,000.00 Net Margins356.25% Pretax MarginN/A Return on Equity-760.96% Return on Assets-26.38% Debt Debt-to-Equity Ratio806.85 Current Ratio3.91 Quick Ratio0.63 Sales & Book Value Annual Sales£1.15 million Price / Sales16.38 Cash FlowGBX 2.12 per share Price / Cash Flow11.96 Book ValueGBX 1 per share Price / Book25.40Miscellaneous Outstanding Shares74,140,000Free FloatN/AMarket Cap£18.83 million OptionableNot Optionable Beta1.12 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Martin John Gouldstone (Age 58)CEO & Director Mr. Martin HudsonFinance DirectorMr. Ron Kirschner (Age 45)COO, General Counsel & Company Secretary Prof. Tariq Sethi B.Sc.FRCP, M.A., M.D., Ph.D., Chief Scientific OfficerMs. Cléa RosenfeldHead of Investor RelationsMr. Maarten BrusseChief Commercial Officer of AsiaMore ExecutivesKey CompetitorsOxford BioDynamicsLON:OBDDestiny PharmaLON:DESTSareumLON:SAROptiBiotix HealthLON:OPTISkinBioTherapeuticsLON:SBTXView All CompetitorsInsidersMartin GouldstoneBought 36,023 shares on 12/8/2023Total: £972,621.00 ($27.00/share)Adam HillBought 48,370 shares on 6/5/2023Total: £1.02 M ($21.00/share)View All Insider Transactions ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed in 2024? Oncimmune's stock was trading at GBX 25.20 at the beginning of the year. Since then, ONC shares have increased by 0.8% and is now trading at GBX 25.40. View the best growth stocks for 2024 here. How were Oncimmune's earnings last quarter? Oncimmune Holdings plc (LON:ONC) posted its quarterly earnings data on Tuesday, February, 13th. The company reported ($5.70) EPS for the quarter. The business earned $0.08 million during the quarter. Oncimmune had a negative trailing twelve-month return on equity of 760.96% and a net margin of 356.25%. What other stocks do shareholders of Oncimmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), Axsome Therapeutics (AXSM), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST). How do I buy shares of Oncimmune? Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:ONC) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersAI “wealth window” is closing June 25thParadigm PressThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsElon to Transform U.S. Economy? Porter & CompanyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncimmune Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
